格隆汇11月21日丨昊帆生物(301393.SZ)公布，第四届董事会第十四次会议、第四届监事会第十二次会 议，分别审议通过了《关于变更部分募集资金用途和部分募投项目结项的议案》和《关于部分募投项目 延期的议案》，具体包括：1."苏州昊帆生物股份有限公司100kg/年多肽、蛋白质试剂研发与生产及总部 建设项目（一期）"基本达到预定可使用状态，本次拟结项，节余资金用于补充流动资金。2.受外部政 策变化的影响，结合公司现阶段经营发展的需要，公司拟变更现有募投项目"安徽昊帆多肽试剂及医药 中间体建设项目"和"多肽及蛋白质试剂研发平台建设项目"中合计49,696.68万元募集资金的用途，投入 于另一募投项目"淮安昊帆生产基地建设项目"的建设；同时，"安徽昊帆多肽试剂及医药中间体建设项 目"和"多肽及蛋白质试剂研发平台建设项目"拟结项，扣除上述变更募集资金金额后的节余资金（系现 金管理收益扣除手续费的净额）用于补充流动资金。3.为保障产能建设安全、快速、有序推进，公司决 定分期建设淮安昊帆生产基地的生产线，因此"淮安昊帆生产基地建设项目"拟延长达到预定可使用状态 的时间至2028年12月。 ...

Core Viewpoint - The company has approved adjustments to its investment projects, expanding capacity and changing the use of raised funds [1] Group 1: Investment Adjustments - The company will hold its fourth board meeting on November 17, 2025, to review the proposal for adjusting the investment scale of certain fundraising projects [1] - The investment scale for the "Ding'an annual production of 5,000 tons of food raw materials project" has been adjusted and expanded, with the project name changed to "Ding'an annual production of 10,000 tons of food raw materials project" [1] - The company plans to reallocate 20 million yuan from the "Cangnan annual production of 30,000 tons of concentrated dairy products production project" to the "Ding'an annual production of 10,000 tons of food raw materials project" [1] Group 2: Capital Increase - The company will also increase its capital by 20 million yuan to Hainan Yeda [1] - This matter will require approval at the company's second extraordinary general meeting in 2025 [1]

Core Viewpoint - The company has decided to terminate the development of prothrombin complex concentrate and shift focus to the more advantageous development of human coagulation factor IX, due to market demand, competitive landscape, and cost-effectiveness considerations [1][2]. Market Demand and Competitive Landscape - The domestic market for prothrombin complex concentrate has seen stable issuance volumes with limited new market space, while the market for human factor IX has fewer competitors and significant growth potential [1]. - Human factor IX is considered a better option for treating hemophilia B due to its lower risk of thrombotic side effects compared to prothrombin complex concentrate [1][2]. Product Comparison Analysis - Prothrombin complex concentrate contains various vitamin K-dependent factors and may pose risks of thrombosis with repeated high-dose use, while human factor IX is purer and has a higher specific activity, making it a safer treatment option [1][2]. Cost-Effectiveness Analysis - The clinical trial approval for prothrombin complex concentrate was obtained in 2008, but the regulatory requirements for production site changes and the need for extensive research have made it less economically viable compared to human factor IX, which has a higher sales price and greater market growth potential [2][4]. Project Background and Investment Plan - The genomic DNA length of human factor IX is approximately 34,000 bp, and the project is expected to complete development and obtain production approval by the end of 2030 [2][4]. - The estimated investment for the development of human factor IX is 60 million yuan, with funding sourced from both raised capital and the company's own funds [4]. Project Benefits and Feasibility - The human factor IX product is aimed at treating patients with factor IX deficiency (hemophilia B), and the limited number of competitors in this market suggests significant future growth opportunities [5]. - The project aligns with market trends and the company's operational needs, enhancing resource allocation and economic benefits, thereby improving profitability and market competitiveness [5][7]. Implementation Timeline - The implementation timeline for the new product development is expected to be completed by the end of 2030, with the associated production line construction already finished [6][4]. Impact of Changes on the Company - The termination of the prothrombin complex concentrate project will reduce the current year's net profit but is expected to enhance the company's future product development and sales capabilities [7]. - The board and supervisory committee have approved the change in fundraising purposes, emphasizing the alignment with the company's operational needs and long-term interests [8][10].

Core Viewpoint - The company has announced a change in the use of raised funds, shifting from overseas projects to domestic mining projects, aiming to optimize fund allocation efficiency and focus on high-quality domestic mining markets [1][2]. Fund Usage Change - The company plans to redirect approximately 1.18 billion yuan of the originally raised 1.2 billion yuan for the "Mining Engineering Construction and Mining Equipment Purchase Project" to the "Anning Mining Panketian Iron Mine Open-pit to Underground Mining Project" [1]. - The original project intended to use funds for equipment procurement in overseas mining projects in countries like the Democratic Republic of Congo and Zambia, but only 185.48 million yuan of the raised funds were utilized, with 72.4% of the total investment completed through self-funding [1][2]. Project Details - The "Anning Mining Panketian Iron Mine Open-pit to Underground Mining Project" has a contract value of 3.8 billion yuan (excluding tax) and a construction period of 1500 calendar days, signed with Anning Mining Co., Ltd. on April 1, 2025 [3]. - The project includes critical mining facilities such as three vertical shafts and a mineral recovery system, with construction having commenced on April 20, 2025 [3]. Financial Performance - As of the end of June, the company reported total revenue of approximately 710 million yuan, reflecting a year-on-year increase of 8.35%, and a net profit attributable to shareholders of approximately 44.71 million yuan, up 3.72% year-on-year [3].

Core Viewpoint - The company announced a change in the use of part of the raised funds, reallocating 50 million yuan from the original project to a new project, which is expected to enhance the efficiency of fund utilization [1] Fund Allocation Changes - The company plans to change the use of 50 million yuan of the raised funds, which represents 3.37% of the net amount raised [1] - The funds were originally intended for the "East China Testing Base Project" and will now be redirected to the "Central China (Wuhan) Testing Base Project" [1] - This change does not involve any new investment projects and does not constitute a related party transaction [1] Governance - The proposal for changing the fund usage will be submitted for approval at the upcoming shareholders' meeting [1]

Core Points - The company did not distribute cash dividends or issue bonus shares during the reporting period [3] - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [5] - The company has made changes to some fundraising investment projects, reallocating 100.409 million yuan from the "Ningxia Quartz Crucible Phase II Project" to a new project, "Semiconductor Quartz Crucible Construction Project" [7] Financial Data - As of June 30, 2025, the remaining convertible bonds "Oujing Convertible Bonds" amounted to 4,693,063 units, with a total face value of 469.306 million yuan [5][6] - During the reporting period, 1,748 units of "Oujing Convertible Bonds" were converted, resulting in an increase of 4,155 shares [5] Important Matters - The company activated the additional repurchase clause for "Oujing Convertible Bonds" due to changes in some fundraising projects, allowing bondholders to exercise a one-time repurchase right [6] - The effective repurchase application quantity during the repurchase period was 30 units [6]

Core Viewpoint - The company is adjusting its fundraising project due to lower-than-expected market demand for its smart cold chain and vending machine products, leading to a change in investment allocation towards a new project in Indonesia [1][4]. Group 1: Project Overview - The total planned investment for the "Smart Cold Chain Equipment and Commercial Vending Machine Industrialization Project" is 652.42 million yuan, with major allocations for site investment (48.41%), equipment purchase and installation (41.15%), working capital (5.96%), and basic reserve funds (4.48%) [1]. - As of June 30, 2025, the project has utilized approximately 264.36 million yuan of the raised funds, with a remaining balance of about 269.54 million yuan [2]. Group 2: Project Progress and Adjustments - The project has not yet reached the expected operational status, with a revised completion date set for December 31, 2025. Land acquisition is complete, and some construction has been finished [2]. - The original project planned to add 32,500 smart cold chain vending machines and 47,500 commercial vending machines, but the slow penetration of the unmanned retail industry and a decline in the fast-moving consumer goods sector have led to a slowdown in project progress [3]. Group 3: Financial Adjustments - As of June 30, 2025, the actual site investment was 185.93 million yuan, which is 129.90 million yuan less than originally planned, and equipment purchase and installation costs were 78.42 million yuan, falling short by 190.08 million yuan [4]. - The company plans to adjust the project scale downwards, resulting in a lower required investment amount. The surplus funds will be redirected to a new project in Indonesia, which requires additional investment due to increased building area and production capacity [4].

Core Viewpoint - Qingdao Hairong Commercial Cold Chain Co., Ltd. announced a change in the use of part of the raised funds for its project due to lower-than-expected market demand and adjustments in project planning [1][2][3][4]. Fund Utilization and Project Details - The "Intelligent Cold Chain Equipment and Commercial Vending Machine Industrialization Project" has a total planned investment of 652.42 million yuan, with 493.74 million yuan intended to be funded by raised capital [1]. - As of June 30, 2025, the project has utilized approximately 264.36 million yuan of the raised funds, leaving a balance of about 269.54 million yuan [2]. - The project has faced delays, with an expected completion date now set for December 31, 2025, due to slower-than-anticipated market penetration in the unmanned retail sector and a decline in the growth rate of the fast-moving consumer goods industry [2][3]. Adjustments in Project Planning - The actual investment in land and equipment has fallen short of the original plan, with land investment at 185.93 million yuan, which is 129.90 million yuan less than planned, and equipment costs at 78.42 million yuan, which is 190.08 million yuan less than planned [3]. - The company has determined that existing production capacity is sufficient to support future domestic business needs, leading to no plans for further large-scale investments in the original project [3]. Reallocation of Funds - The company plans to reallocate over 90 million yuan of the remaining raised funds to a new project in Indonesia, which involves establishing a subsidiary and building a commercial display cabinet manufacturing plant [4]. - This reallocation is necessary due to increased construction area, adjustments in production line layout, and the need for additional production equipment to enhance the production capacity of intelligent vending machines and commercial vending machines [4].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 建議變更H股募集資金用途 H股募集資金基本情況 茲提述(i)本公司日期為2015年7月28日 的H股 招 股 說 明 書（「招股書」）, (ii) 本公司日期為2020年3月25日的建議變更H股 募 集 資 金 用 途 公 告（「該公告」） 及(iii)本公司日期為2020年5月15日的本公司2019年 度 股 東 週 年 大 會 通 函， 內 容 有 關（其 中 包 括）本 公 司H股募集資金基本情況及變更H股募集資金 用 途。除 另 有 界 定 者 外，本 公 告 所 用 詞 彙 與 招 股 書 及 該 公 告 所 界 定 者 具 有 相 同 涵 義。 中 國 鐵 路 通 信 信 號 股 份 有 限 公 司 China Railway Signal & Communication Corporation Limited* （在中華人 ...

Core Viewpoint - The company has approved several resolutions during its board meetings, including changes in the use of raised funds and the establishment of a wholly-owned subsidiary in Shenzhen for a research and design center, aimed at enhancing its core competitiveness and optimizing fund utilization [10][33][49]. Group 1: Company Overview - The company is named Hunan Hualian Ceramics Co., Ltd. and is publicly listed with the stock code 001216 [1]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [5][6]. Group 2: Financial and Operational Decisions - The board approved a resolution to change the use of part of the raised funds amounting to 71.48 million yuan (including interest) from the engineering technology center project to the Shenzhen research and design center project [10][24]. - The total investment for the Shenzhen research and design center project is 130 million yuan, with the company planning to use up to 100 million yuan for purchasing office space [11][26]. Group 3: Related Party Transactions - The company has approved a new annual related party transaction with Hunan Yaran Porcelain Trading Co., Ltd., with an estimated total amount not exceeding 130,000 yuan for 2025 [53][54]. - The related party transactions are conducted based on fair market pricing and do not harm the company's interests [9][63]. Group 4: Upcoming Events - The company plans to hold its fourth extraordinary general meeting of shareholders on September 11, 2025, to discuss various proposals, including the changes in the use of raised funds [66][67].